Cartalax
Cartalax is the tripeptide Ala-Glu-Asp, or AED. Cell studies found changes in selected aging-related markers in human skin fibroblasts and embryo-derived bone-marrow cells. A 29-person applicant-written patent example reported knee pain and movement improvement but omitted the group results and statistics needed to judge the effect.
synthetic Ala-Glu-Asp tripeptide
- Sequence AED
- PubChem CID 87815447
- Published human-cell studies did not use cartilage cells
- Human knee claim comes from a patent example
- No independently published controlled clinical trial in the cited records
What is Cartalax?
Cartalax is Ala-Glu-Asp, abbreviated AED. It is different from AEDG Epithalon, EDR Pinealon, KED peptides, and complex cartilage extracts.
PubChem · Cartalax identity
Government chemical database
NIH PubChem CID 87815447.
The database record defines alanyl-glutamyl-aspartic acid, the tripeptide abbreviated AED. Database identity does not authenticate a retail vial or establish a treatment effect.
- Study design
- Curated chemical identity record
Cell study · aging-related genes
In-vitro study
Ashapkin V et al. Molecular Biology Reports, 2020.
AED, KED, and KE were applied to cultured human embryo bone-marrow mesenchymal stem cells. The peptides changed expression of selected genes including IGF1 and NF-kappa-B. No participant received a peptide, and the experiment did not isolate AED across every comparison.
- Participants / model
- Cultured human embryo bone-marrow mesenchymal stem cells
- Treatment
- Nanomolar AED, KED, or KE
- Study design
- Cell-culture gene-expression study
Does Cartalax improve knee osteoarthritis?
A 29-person applicant-written patent example reported pain reduction and improved movement. It omitted clear group results, blinding, attrition, baseline balance and adequate statistics, and no independent controlled trial has confirmed the result.
Why is the patent example weak evidence?
It omits the information needed to judge bias and effect size: clear group allocation, blinding, attrition, baseline balance, group results, and adequate statistics. It also reports no significant radiographic change.
WO2007139433 · applicant-written human example
Patent example
World Intellectual Property Organization, WO2007139433.
Example 5 describes 29 people with knee osteoarthritis and says 12 controls received saline. It reports symptom claims but does not provide adequate allocation, blinding, attrition, baseline, group-level results, statistical analysis, or a significant radiographic change. The patent is applicant-written rather than an independent peer-reviewed trial.
- Participants / model
- 29 people described as having knee osteoarthritis
- Treatment
- Cartalax or saline according to the patent example
- Study design
- Poorly reported applicant-written example
The patent supplies no independent peer review or analyzable group-level results.
Read the original sourceWO2007139433 · applicant-written human example
Patent example
World Intellectual Property Organization, WO2007139433.
Example 5 describes 29 people with knee osteoarthritis and says 12 controls received saline. It reports symptom claims but does not provide adequate allocation, blinding, attrition, baseline, group-level results, statistical analysis, or a significant radiographic change. The patent is applicant-written rather than an independent peer-reviewed trial.
- Participants / model
- 29 people described as having knee osteoarthritis
- Treatment
- Cartalax or saline according to the patent example
- Study design
- Poorly reported applicant-written example
The patent supplies no independent peer review or analyzable group-level results.
Read the original sourceCited records · no independent trial
Literature and registry record set
PubMed, ClinicalTrials.gov, and Russian-language records.
The cited records under Cartalax, Карталакс, Ala-Glu-Asp, AED peptide, and alanyl-glutamyl-aspartic acid contain no registered intervention trial or independent peer-reviewed controlled human trial. A Russian commercial product page links a seller-hosted clinical report and the same developer patent example, not an independently indexed journal trial.
- Study design
- Latin name, Cyrillic name, sequence, chemical-name, and patent coverage
What do the laboratory studies show?
AED altered selected gene-expression and protein markers in human embryo-derived mesenchymal stem cells and aging human skin fibroblasts. Neither paper studied cartilage cells, drug delivery to a human joint, or cartilage rebuilding after oral or injected AED.
Cell study · aging-related genes
In-vitro study
Ashapkin V et al. Molecular Biology Reports, 2020.
AED, KED, and KE were applied to cultured human embryo bone-marrow mesenchymal stem cells. The peptides changed expression of selected genes including IGF1 and NF-kappa-B. No participant received a peptide, and the experiment did not isolate AED across every comparison.
- Participants / model
- Cultured human embryo bone-marrow mesenchymal stem cells
- Treatment
- Nanomolar AED, KED, or KE
- Study design
- Cell-culture gene-expression study
Human skin cells · not cartilage
In-vitro study
Khavinson VK et al. Bulletin of Experimental Biology and Medicine, 2016.
KE, KED, AED, and AEDG were applied to aging human skin-fibroblast cultures. All four altered selected proliferation, aging, and extracellular-matrix protein markers; AED and AEDG also reduced a caspase-3 apoptosis marker. The experiment did not study cartilage cells, joints, pain, function, imaging, or treated people.
- Participants / model
- Aging cultured human skin fibroblasts
- Treatment
- In-vitro KE, KED, AED, or AEDG exposure
- Study design
- Cell-culture immunofluorescence study
What is known about safety?
The patent example and cell studies do not provide an adequate human safety profile. Pharmacokinetics, immune effects, repeated exposure, pregnancy, interactions, and product quality remain unknown.
Short sequence length does not make a product automatically safe. Route, formulation, impurities, sterility, endotoxin, and degradation still matter.
WO2007139433 · applicant-written human example
Patent example
World Intellectual Property Organization, WO2007139433.
Example 5 describes 29 people with knee osteoarthritis and says 12 controls received saline. It reports symptom claims but does not provide adequate allocation, blinding, attrition, baseline, group-level results, statistical analysis, or a significant radiographic change. The patent is applicant-written rather than an independent peer-reviewed trial.
- Participants / model
- 29 people described as having knee osteoarthritis
- Treatment
- Cartalax or saline according to the patent example
- Study design
- Poorly reported applicant-written example
The patent supplies no independent peer review or analyzable group-level results.
Read the original sourceCited records · no independent trial
Literature and registry record set
PubMed, ClinicalTrials.gov, and Russian-language records.
The cited records under Cartalax, Карталакс, Ala-Glu-Asp, AED peptide, and alanyl-glutamyl-aspartic acid contain no registered intervention trial or independent peer-reviewed controlled human trial. A Russian commercial product page links a seller-hosted clinical report and the same developer patent example, not an independently indexed journal trial.
- Study design
- Latin name, Cyrillic name, sequence, chemical-name, and patent coverage
Is Cartalax approved?
FDA and ClinicalTrials.gov records contain no approved Cartalax drug, prescribing label, or registered human intervention trial. A patent grants intellectual-property rights; it does not approve a medicine.
WO2007139433 · applicant-written human example
Patent example
World Intellectual Property Organization, WO2007139433.
Example 5 describes 29 people with knee osteoarthritis and says 12 controls received saline. It reports symptom claims but does not provide adequate allocation, blinding, attrition, baseline, group-level results, statistical analysis, or a significant radiographic change. The patent is applicant-written rather than an independent peer-reviewed trial.
- Participants / model
- 29 people described as having knee osteoarthritis
- Treatment
- Cartalax or saline according to the patent example
- Study design
- Poorly reported applicant-written example
The patent supplies no independent peer review or analyzable group-level results.
Read the original sourceCited records · no independent trial
Literature and registry record set
PubMed, ClinicalTrials.gov, and Russian-language records.
The cited records under Cartalax, Карталакс, Ala-Glu-Asp, AED peptide, and alanyl-glutamyl-aspartic acid contain no registered intervention trial or independent peer-reviewed controlled human trial. A Russian commercial product page links a seller-hosted clinical report and the same developer patent example, not an independently indexed journal trial.
- Study design
- Latin name, Cyrillic name, sequence, chemical-name, and patent coverage
Studies and sources
PubChem · Cartalax identity
Government chemical database
NIH PubChem CID 87815447.
The database record defines alanyl-glutamyl-aspartic acid, the tripeptide abbreviated AED. Database identity does not authenticate a retail vial or establish a treatment effect.
- Study design
- Curated chemical identity record
Cell study · aging-related genes
In-vitro study
Ashapkin V et al. Molecular Biology Reports, 2020.
AED, KED, and KE were applied to cultured human embryo bone-marrow mesenchymal stem cells. The peptides changed expression of selected genes including IGF1 and NF-kappa-B. No participant received a peptide, and the experiment did not isolate AED across every comparison.
- Participants / model
- Cultured human embryo bone-marrow mesenchymal stem cells
- Treatment
- Nanomolar AED, KED, or KE
- Study design
- Cell-culture gene-expression study
Human skin cells · not cartilage
In-vitro study
Khavinson VK et al. Bulletin of Experimental Biology and Medicine, 2016.
KE, KED, AED, and AEDG were applied to aging human skin-fibroblast cultures. All four altered selected proliferation, aging, and extracellular-matrix protein markers; AED and AEDG also reduced a caspase-3 apoptosis marker. The experiment did not study cartilage cells, joints, pain, function, imaging, or treated people.
- Participants / model
- Aging cultured human skin fibroblasts
- Treatment
- In-vitro KE, KED, AED, or AEDG exposure
- Study design
- Cell-culture immunofluorescence study
WO2007139433 · applicant-written human example
Patent example
World Intellectual Property Organization, WO2007139433.
Example 5 describes 29 people with knee osteoarthritis and says 12 controls received saline. It reports symptom claims but does not provide adequate allocation, blinding, attrition, baseline, group-level results, statistical analysis, or a significant radiographic change. The patent is applicant-written rather than an independent peer-reviewed trial.
- Participants / model
- 29 people described as having knee osteoarthritis
- Treatment
- Cartalax or saline according to the patent example
- Study design
- Poorly reported applicant-written example
The patent supplies no independent peer review or analyzable group-level results.
Read the original sourceCited records · no independent trial
Literature and registry record set
PubMed, ClinicalTrials.gov, and Russian-language records.
The cited records under Cartalax, Карталакс, Ala-Glu-Asp, AED peptide, and alanyl-glutamyl-aspartic acid contain no registered intervention trial or independent peer-reviewed controlled human trial. A Russian commercial product page links a seller-hosted clinical report and the same developer patent example, not an independently indexed journal trial.
- Study design
- Latin name, Cyrillic name, sequence, chemical-name, and patent coverage
Why is Cartalax in C tier?
C tier rests on a defined molecule and direct cell research. The only cited human knee claim comes from a poorly reported patent example, with no independent controlled trial to validate osteoarthritis treatment.